The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment
|
|
- Vivien Johns
- 5 years ago
- Views:
Transcription
1 Journal of Gerontology: MEDICAL SCIENCES 2002, Vol. 57A, No. 7, M414 M418 Copyright 2002 by The Gerontological Society of America The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment M Ihab Hajjar, Jeannie Schumpert, Victor Hirth, Darryl Wieland, and G. Paul Eleazer Palmetto Health Alliance/University of South Carolina, Columbia. Background. Previous evidence suggests that treatment with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors (statins) has a positive impact on dementia. We decided to investigate the association between the use of statins and the prevalence of dementia and statins impact on the progression of cognitive impairment. Methods. This is a case-control and a retrospective cohort study of a community-based ambulatory primary care geriatric practice. We included a convenience sample of all patients (N 655, mean age years, 85% Caucasian, 74% women) with hypercholesterolemia or dementia, or using statins. We compared those using statins with those who do not with respect to the clinical diagnosis of dementia and its subtypes and the progression of cognitive impairment. Results. At the initial visit, 35% had dementia, and 17% were using statins. After covariate adjustments, patients on statins were less likely to have dementia (odds ratio [OR] for dementia based on composite definition 0.23; 95% confidence interval [CI] [ ], p.001, OR Alzheimer s disease 0.37; 95% CI [ ], p.005, OR vascular dementia 0.25; 95% CI [ ], p.027). At follow-up, patients on statins showed an improvement on their Mini-Mental Status Examination score by compared to a decline by in controls, p.025 (OR for no change or improvement on statins 2.81; 95% CI [ ], p.045) and scored higher on the Clock Drawing Test (difference of , p.036). Conclusions. The use of statins is associated with a lower prevalence of dementia and has a positive impact on the progression of cognitive impairment. ANY studies, both cross-sectional and longitudinal, have found an association between metabolic cardiovascular syndromes and dementia (1 6). Hyperlipidemia in particular has been identified as a possible risk factor for both vascular dementia and Alzheimer s disease (AD) (5,7 13). This risk relationship is supported by animal models and cross-national surveys. For example, mice fed a highcholesterol diet have a twofold increase in the -amyloid protein and an increase in the number and size of amyloid deposits (14). Countries that have high dietary fat consumption tend also to have a higher prevalence of AD (6). It is theoretically possible then that treatment of hyperlipidemia could lessen the risk of dementia and slow the progression of the disease. In fact, prior preliminary data have shown that individuals treated with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors (statins) have a lower prevalence of dementias of both vascular and Alzheimer s types (14,15). However, data are very sparse concerning the impact of statins on the progression of cognitive impairment in individuals with hyperlipidemia or dementia. We conducted a retrospective study on the association between statin use and the prevalence of dementia and the progression of cognitive impairment using chart review of elements of a standardized geriatric assessment and medication records of patients of a primary care geriatric practice. METHODS This is a case-control and a retrospective cohort study of patients of the Richland Senior Primary Care Practice, a community-based, medical school-affiliated practice in Columbia, South Carolina. All practice physicians are trained geriatricians. When patients establish primary care in this practice, health and diagnostic information is recorded. Comprehensive health, functional, and diagnostic information is recorded in a database when patients enroll. Followup functional information is scheduled for collection and entry approximately annually. Diagnostic and medication information is also periodically abstracted from practice charts and entered. Patients selected for this study were all those with the diagnosis of hypercholesterolemia or dementia (AD, vascular dementia, mixed-type dementia, or Diffuse Lewy Body disease) or patients using statins. Because the practice was relatively new, all patients enrolled between 1997 and Data recorded at the initial visit included age, gender, race, smoking history, alcohol consumption, level of education, family history of dementia or AD, clinical diagnosis of hypertension, stroke, transient ischemic attack (TIA), and depression. All patients diagnosed with hypercholesterolemia and dementia were noted. When available, date of onset and type of dementia (AD, vascular dementia, mixed-type de- M414
2 STATINS AND DEMENTIA M415 mentia, or Diffuse Lewy Body disease) were recorded. Cognitive and mood assessments were performed at baseline and follow-up. The Folstein Mini-Mental Status Examination (MMSE) (16), Clock Drawing Test (CDT) (17), and the Geriatric Depression Scale (GDS) (18,19) were administered by a trained geriatric social worker to all patients, using a uniform procedure. Two social workers performed all the testing, minimizing interoperator variability. We use the scale of 7 (with 7/7 as the perfect score) for CDT scoring. Statin use at baseline and duration of use were also recorded. To confirm use of statins, prescriptions written and provided to patients during the period of follow-up were recovered from the charts. In addition, we extracted data on baseline and continuing use of aspirin, donepezil (Aricept), vitamin B12, and vitamin E. Physical exam information included blood pressure readings and heart rate. We used the higher of the left or right arm while sitting. Laboratory information included total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride (TG). We used only values obtained in our local laboratory to minimize variations. For follow-up examinations, we extracted information on blood pressure, heart rate, cholesterol level, LDL, HDL, and TG from charts as well as medications used, MMSE, CDT, and GDS. To operationalize the diagnosis of dementia for this study, we developed a composite variable with a positive diagnosis when both a clinical diagnosis of dementia or one of its types were documented in the chart and the patient had a MMSE score less than 24. This cutoff has been shown to improve diagnostic accuracy (20). We performed the analysis using this composite variable, as well as each individual diagnostic criterion (clinical diagnosis and MMSE score). For the longitudinal analysis of cognitive change, we used the absolute change in MMSE score and CDT score between the follow-up cognitive testing and baseline testing at the initial visit. Practice enrollment data were used for the analysis of dementia/cognitive impairment prevalence. The study of cognitive status change was conducted on patients for whom follow-up cognitive testing data were available. Patients were assigned to the statin group (those using statins at the initial visit) or the control group (not using statins). Review of the control charts indicated that none of the patients in this group had been exposed to statins. A chi-square test compared prevalence of dementia in the two groups. Bivariate and multivariate analyses were employed to explore the impact of other potential dementia risk factors. Multiple logistic, linear regression, and stepwise regression techniques were used to develop models, adjusting for multiple covariates. Goodness-of-fit tests were used to select the best-fitted models (21). Covariates included age, gender, race, education, smoking, alcohol, blood pressure, medical diagnoses (stroke or TIA, hypertension, depression), family history of dementia or AD, cholesterol level, LDL, HDL, and TG. Table 1. Baseline Characteristics at the Initial Visit of the Overall Sample, the Statin Group, and the Control Group Characteristic Overall Control Group Statin Group n (83%) 113 (17%) Age* (in years) Gender (Male) 26% 26% 23% Race 85% W 15% B 84% W 16% B 88%W 12% B Family History of Dementia* 30% 32% 23% Hypercholesterolemia* 36% 24% 96% Hypertension* 61% 24% 95% Stroke 19% 19% 16% Transient Ischemic Attacks 3% 4% 2% Depression 45% 45% 45% Aricept* 15% 16% 7% Aspirin* 32% 30% 43% Vitamin B12* 6% 5% 12% Vitamin E* 17% 15% 25% SBP* (mmhg) DBP (mmhg) Cholesterol Level* (mg/dl) LDL* HDL Triglyceride Geriatric Depression Scale Education (in years) Alcohol Use Smoking 30% C 4% P 66% N 8% C 55% N 28% C 4% P 68% N 7% C 56% N 38% C 2% P 60% N 12% C 51% N Note: B Black; W White; C current users; P past users; N never users; SBP systolic blood pressure; DBP diastolic blood pressure; LDL lowdensity lipoprotein; HDL high-density lipoprotein. *p.05 for the difference between the statin and the control groups.
3 M416 HAJJAR ET AL. Models were tested for the composite variable, clinical diagnosis of dementia, AD, vascular dementia, mixed dementias, MMSE, and CDT. The institutional review board approved the study at the local institution. RESULTS We identified 655 eligible patients (mean age years, range 52 to 98 years, 85% Caucasian, 15% African American, and 74% women) (Table 1). Sixty percent had dementia based on chart diagnosis, and 48% had an MMSE score less than 24 (concordance rate was 89%, p.001). Of all patients selected, 233 (35.4%) were positive for dementia using the composite variable. Twenty-three percent had a clinical diagnosis of AD, 9% had vascular dementia, 4% had mixed-type dementia, 0.5% had Diffuse Lewy Body disease, and 63.5% had dementia not otherwise specified. One hundred and thirteen (17%) patients were using statins on the initial visit and 17% on follow-up. Of the sample selected, 165 (25%) patients had follow-up MMSE, and 82 (12%) had follow-up CDT. The mean follow-up period was months (range 0 to 40.2 months). Apart from race and family history of dementia, there were no differences between the patients who had follow-up cognitive testing available in their records and those who did not (Table 2). Cognitive function was not different between the groups with and without follow-up cognitive testing (MMSE score of and CDT score of in the group with follow-up vs and in the group without follow-up, p.47 and p.59, respectively). There was no difference between the two groups in the percentage of patients on statin (14% in the group with vs 18% in the group without follow-up, p.193). Data on the duration of dementia were not available in the records of the selected sample and could not be included in the analysis. On the initial visit, the statin group was less likely to have dementia based on the chart diagnosis, MMSE criterion, and composite variable definition (22% of those on statins had dementia based on chart diagnosis vs 68% in the control group, p.001, 15% of the statin group had dementia using the MMSE criterion vs 56% in the control group, p.001, 24% of the statin group had dementia based on the composite variable definition vs 73% in the control group, p.001). This was also true for AD (9% in the statin group vs 25% in the controls, p.001) and vascular dementia (3% in the statin group vs 10%, p.001). There was no difference in those diagnosed with mixed dementia or Diffuse Lewy Body disease. All models developed to adjust for covariates showed a persistent association. After adjusting for age, gender, race, education, blood pressure, family history of dementia, cholesterol, LDL and triglyceride levels, clinical diagnosis of stroke, TIA, depression, and hypertension, GDS, use of alcohol and smoking, and medications used, current use of statin was associated with a lower risk of dementia based on all criteria and for both AD and vascular dementia (odds ratio [OR] for dementia based on composite definition 0.23; 95% confidence interval [CI] [ ], p.001; OR for dementia based on chart diagnosis 0.16; 95% CI [ ], p.001; OR based on MMSE cutpoint Table 2. Comparison Between Patients Who Had Versus Those Who Did Not Have Characteristic Patients With Patients Without n Age (in years) Gender (Male) 73% 75% Race* 83% W 17% B 91% W 9% B Family History of Dementia 36% 28% Hypertension 61% 62% Stroke 18% 18% Depression 50% 43% Statins 14% 18% Aricept 14% 15% Aspirin 36% 31% Vitamin B12 7% 6% Vitamin E 17% 15% SBP (mmhg) DBP (mmhg) Cholesterol Level (mg/dl) LDL HDL Triglyceride Geriatric Depression Scale Education (in years) Alcohol Use 34% C, 5% P, 61% N 28% C, 4% P, 68% N Smoking 8% C,, 55% N 8% C, 38% P, 54% N Note: B Black; W White; C current users; P past users; N never users; SBP systolic blood pressure; DBP diastolic blood pressure; LDL low-density lipoprotein; HDL high-density lipoprotein. *p.021 for the difference between the 2 groups. p.044 for the difference between the 2 groups. 0.23; 95% CI [ ], p.001; OR for AD 0.37; 95% CI [ ], p.005; OR for vascular dementia 0.25; 95% CI [ ], p.027) (Figure 1). Mean MMSE for the statin group was versus in the control group (p.0001) and mean CDT was versus (p.0001). Multiple regression models with the covariate adjustments showed that the statin group had a higher MMSE (statin group 2.4 [standard deviation 0.8] points higher than the control group, p.001). This was also true for the CDT (statin group had points higher than the control group, p.001). When compared with the cognitive testing at the initial visit, the statin group showed an improvement in their MMSE scores by versus a decline of points in the control group at follow-up (p.025) (Figure 2). After covariate adjustments including other medication use, patients on statins were more likely to show improvement or no change as compared to the control group (OR of having an improvement or no change on their MMSE 2.81; 95% CI [ ], p.045). In addition, at followup, the statin group persistently had higher CDT scores as compared with the control group (p.036) (Table 3). DISCUSSION This study explores the impact of the use of cholesterollowering drugs in the statin class on both the prevalence of
4 STATINS AND DEMENTIA M417 Figure 1. Odds ratio of having dementia in the statin group compared with the control group. p.05 for all categories. Models adjusted for all covariates. Figure 2. Change of Mini-Mental Status Examination (MMSE) score at follow-up after months in the statin versus control group. p value for the comparison of the two groups.025. Delta is the score at follow-up score at baseline on the initial visit. dementia and the progression of cognitive impairment. Our study confirms prior observations that have found a lower prevalence of dementia in patients using statins (15,22). These observations, as in the current study, have found this association to be true for both AD and vascular dementia (15,22). We have found that patients using statins have higher scores on cognitive testing compared to patients not using statins. In addition, we identified an association between statins and an arrest in the progression of cognitive impairment. There is increasing evidence to suggest an important role of cholesterol in the pathophysiology of dementia and AD (7,8,11,12,23 25). For example, Jarvik and colleagues found an increased risk of AD in patients with hypercholesterolemia (8). In the Rotterdam study, hyperlipidemia was found to be associated with vascular dementia and AD (3). Statins lower cholesterol levels by inhibiting cholesterol synthesis, decreasing LDL circulation, and modulating the LDL receptor (26). In addition, statins have an effect on nitric oxide, decrease endothelin, and may have an antioxidant effect (27 30). The mechanism of the potential effect of statins on dementia and cognitive impairment is unknown. Our study showed an association between the use of statins and dementia, both vascular dementia and AD. This association was persistent even after adjusting for cholesterol, LDL levels, and stroke, suggesting that the effect of statins is independent of their effect on cholesterol and stroke prevention. One limitation of this study is bias by indication (31, 32), which implies that statins are less likely to be prescribed to patients with dementia. Although we understand that this is a major problem of any cross-sectional or retrospective analysis that investigates the impact of an intervention, both the control and the statin groups were similar in many risk factors for dementia. Both groups were similar in education, alcohol consumption, tobacco use, stroke or TIA, and depression. We also performed multivariate analyses controlling for many covariates that could potentially affect the physicians prescribing of the statin drugs. The impact of statins on dementia prevalence remained after these adjustments, minimizing the impact of this bias. Also, the association was persistent in the longitudinal analysis at follow-up, suggesting that the effect of statins is more likely to be valid and not only due to the bias by indication. Another limitation of this study is the accuracy of the diagnosis of dementia. We were not able to confirm the diagnosis of dementia or its subtypes in the patients selected. The diagnosis of dementia is mostly a clinical diagnosis that is relatively accurate (33). We used two cognitive measures and developed a composite variable based on the clinical diagnosis and cognitive testing, which should improve diagnostic accuracy. The high rate of concordance between the clinical diagnosis and the cognitive testing results suggests accuracy of the diagnosis of dementia. In our sample, the majority of patients with a clinical diagnosis of dementia had no documented subtype. The impact of statins was true for these patients as well as for the overall sample and for those with either vascular dementia or AD, making the impact of this limitation on our results relatively low. In part due to the recent growth in patient enrollment, many patients did not have follow-up cognitive testing. This limited our ability to perform subgroup analysis. There were no differences, including in cognitive testing score at baseline or use of statins, between the patients who had documented cognitive testing on follow-up and those who did not. Therefore, missing data from our analysis most likely have little impact on our results. We had little information on patients compliance with the use of statins. The finding that the mean cholesterol and LDL of the statin group was lower than the control group suggests that the patients were using the prescribed drugs. Our study was not designed to test the impact of other lipidlowering agents or to compare the differences between the multiple statin drugs. We did not assess the incidence of adverse drug reaction from statins or the rate of drug withdrawal. A similar percentage of patients was using statins at baseline and at follow-up. We also could not assess the impact of statins on cognition beyond the follow-up period.
5 M418 HAJJAR ET AL. Table 3. Score Difference Between the Statin Group and the Control Group at Baseline and at in the Multivariate Analysis Clock Drawing Test Statin Group P Value Baseline n* (19%) Delta standard error n* (21%) Delta standard error *n represents the number of patients for whom Clock Drawing Test data were available. Delta is the difference between the statin group and the control group and is calculated using the final multivariate model. R 2 20% for the initial visit and 30.2% for the follow-up in the final model. Until a randomized trial is performed, evidence concerning the impact of statins on dementia and their potential benefit for cognitive function will depend largely on observational studies. Our study suggests that the use of statins is associated with a lower prevalence of vascular dementia and AD. In addition, we have found a potential benefit of the use of statins on the progression of cognitive impairment in a select group of older patients followed in a community-based primary care geriatric practice. Clinical trials are urgently needed to confirm the positive impact of these drugs on cognitive function and dementia. Acknowledgment Address correspondence to Ihab Hajjar, MD, MS, Clinical Assistant Professor, Department of Internal Medicine, Division of Geriatrics, Palmetto Health Alliance/University of South Carolina, 9 Medical Park, Suite 230, Columbia, SC ihab.hajjar@palmettohealth.org References 1. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol. 2000;20: Skoog I. Risk factors for vascular dementia: a review. Dementia. 1994;5: Hoffman A, Ott A, Breteler MMB, et al. Atherosclerosis, lipoprotein E, and the prevalence of dementia and Alzheimer s disease in the Rotterdam Study. Lancet. 1997;349: Landin K, Blennow K, Wallin A, Gottfries CG. Low blood pressure and blood glucose levels in Alzheimer s disease: evidence for a hypometabolic disorder? J Intern Med. 1993;233: Craft S, Peskend E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1988;50: Kalmign S, Launer LJ, Ott A, Wittman JCM, Hofman A, Breteler MMB. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol. 1997;42: Sparks DL. Coronary artery disease, hypertension, apo E, and cholesterol: a link to Alzheimer s disease? Ann N Y Acad Sci. 1997;826: Jarvik G, Wijsman E, Kukull W, Schellenberg G, Yu C, Larson E. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer s disease: a case-control study. Neurology. 1995;45: Romas SN, Tang MX, Berglund L, Mayeux R. Apo E genotype, plasma lipid, lipoproteins and Alzheimer s disease in community elderly. Neurology. 1999;53: Launer LJ, Ross W, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu Asia Aging Study. Neurobiol Aging. 2000;21: Jarvick GP, Austin MA, Fabitz RR, et al. Genetic influences on age related change in total cholesterol, low density lipoprotein cholesterol, triglyceride levels: longitudinal lipoprotein E genotype effects. Genet Epidemiol. 1994;11: Notkola IL, Sulkava R, Pekkanen J, et al. Serum cholesterol, apolipoprotein E, epsilon 4 allele and Alzheimer s disease. Neuroepidemiology. 1998;17: Roher AE, Kuo YM, Kokjohn KM, Emmerling MR, Gracon S. Amyloid and lipids in the pathology of Alzheimer s disease. Amyloid. 1999;6: Refolo LM, Pappolla MA, Malester B, et al. Hypercholesterolemia accelerates the Alzheimer s amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7(4): Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57(10): Folstein MF, Folstein SE, McHugh PR. Mini-mental state : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3): Tuokko H, Hadjistavropoulos T, Miller JA, Beattie BL. The Clock Test: a sensitive measure to differentiate normal elderly from those with Alzheimer disease. J Am Geriatr Soc. 1992;40(6): Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1): Almeida OP, Almeida SA. Short versions of the Geriatric Depression Scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatry. 1999;14(10): Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242): Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer s disease in late onset families. Science. 1993;261: Simons M, Keller P, De Strooper B, Beyreuther K, Dotti C, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 1998;95: Hyman B, Strickland D, Rebeck W. Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer s disease. Arch Neurol. 2000;57: Knopp R. Drug treatment of lipid disorders. N Engl J Med. 1999;341: Hess D, Demchuk A, Brass L, Yatsu F. HMGCoA reductase inhibitors: a promising approach to stroke prevention. Neurology. 2000;54: Kaesemeyer W, Caldwell R, Huang J, Caldwell R. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999;33: de la Monte SM, Lu B, Sohn Y, et al. Aberrant expression of nitric oxide synthase III in Alzheimer s disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging. 2000;2: Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol.1999;10: Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci. 2001;187(1 2): Birkenhager WH, Wang JG, Staessen JA. Dementia and statins. Lancet. 2001;357(9259): Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9): Received February 13, 2002 Accepted February 15, 2002
ORIGINAL CONTRIBUTION. Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
ORIGINAL CONTRIBUTION Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women Kristine Yaffe, MD; Elizabeth Barrett-Connor, MD; Feng Lin, MS; Deborah Grady, MD Background: Few strategies
More informationORIGINAL INVESTIGATION. Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease
Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease The Framingham Study ORIGINAL INVESTIGATION Zaldy Sy Tan, MD, MPH; Sudha Seshadri, MD; Alexa Beiser, PhD; Peter W. F. Wilson, MD; Douglas
More informationCLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD. Statin Use and the Risk of Incident Dementia
CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD Statin Use and the Risk of Incident Dementia The Cardiovascular Health Study Thomas D. Rea, MD, MPH; John C. Breitner, MD; Bruce M. Psaty, MD, PhD; Annette
More informationORIGINAL CONTRIBUTION. Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
ORIGINAL CONTRIBUTION Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease Miia Kivipelto, MD, PhD; Tiia Ngandu, BM; Laura Fratiglioni, MD, PhD; Matti Viitanen, MD,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationThe Second Report of the Expert Panel on Detection,
Blood Cholesterol Screening Influence of State on Cholesterol Results and Management Decisions Steven R. Craig, MD, Rupal V. Amin, MD, Daniel W. Russell, PhD, Norman F. Paradise, PhD OBJECTIVE: To compare
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationStatins and Cognition A Focus on Mechanisms
Statins and Cognition A Focus on Mechanisms Note: Deleted copyrighted graphs/tables are described In red text and source references are provided Disclosures: SPARCL Steering Committee and past consultant
More informationORIGINAL INVESTIGATION. Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia
ORIGINAL INVESTIGATION Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia Annika Rosengren, MD, PhD; Ingmar Skoog, MD, PhD; Deborah Gustafson, PhD; Lars Wilhelmsen, MD,
More informationRisk Factors for Vascular Dementia: A Hospital-Based Study in Taiwan
22 Risk Factors for Vascular Dementia: A Hospital-Based Study in Taiwan Jun-Cheng Lin 1,2, Wen-Chuin Hsu 1, Hai-Pei Hsu 1,2, Hon-Chung Fung 1, and Sien-Tsong Chen 1 Abstract- Background: In Taiwan, next
More informationAssociation of statin use with risk of dementia: A meta-analysis of prospective cohort studies
bs_bs_banner Geriatr Gerontol Int 2013; 13: 817 824 REVIEW ARTICLE Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies Yu Song, 1 Hongwei Nie, 2 * Yong Xu, 1
More informationKey Words: Hypertension, Blood pressure, Cognitive impairment, Age 대한신경과학회지 22 권 1 호
Seul-Ki Jeong, M.D., Hae-Sung Nam, M.D., Min-Ho Shin, M.D., Sun-Seok Kweon, M.D., Myong-Ho Son, M.D., Eui-Ju Son, M.D., Jae-Min Kim, M.D., Ki-Hyun Cho, M.D. Background: It has been reported that the association
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationThe Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults
The Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults. Introduction Glucose intolerance is common in older individuals and this metabolic
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationReview Article Total Cholesterol and the Risk of Parkinson s Disease: A Review for Some New Findings
SAGE-Hindawi Access to Research Parkinson s Disease Volume 2010, Article ID 836962, 6 pages doi:10.4061/2010/836962 Review Article Total Cholesterol and the Risk of Parkinson s Disease: A Review for Some
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationMetabolic syndrome is a constellation of cardiovascular
and Cognitive Decline in Elderly Latinos: Findings from the Sacramento Area Latino Study of Aging Study Kristine Yaffe, MD, wzk Mary Haan, DrPH, MPH, z Terri Blackwell, MA, # Elena Cherkasova, BA, Rachel
More informationORIGINAL CONTRIBUTION. Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
ORIGINAL CONTRIBUTION Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease Preliminary Results D. Larry Sparks, PhD; Marwan N. Sabbagh, MD; Donald J. Connor, PhD, PhD; Jean Lopez, MSN,
More informationLIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:
More informationDuring the last 2 decades, evidence has accumulated that a high cholesterol level may
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD Cholesterol Level and Statin Use in Alzheimer Disease I. Review of Epidemiological and Preclinical Studies Nina E. Shepardson, MS; Ganesh M. Shankar,
More informationIN ADDITION TO THE WELL-DOCUmented
ORIGINAL CONTRIBUTION Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE 4 The Cardiovascular Health Study Cognition Study Fumiko Irie, MD, PhD, MPH; Annette L. Fitzpatrick, PhD;
More information김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과
치매예방을위한만성질환관리전략 김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과 A sharp rise in the death rate from Alzheimer s disease Ivan Casserly & Eric Topol, Lancet 2004 Potential for primary prevention of Alzheimer s disease Alzheimer
More informationReduced lung function in midlife and cognitive impairment in the elderly
Page 1 of 5 Reduced lung function in midlife and cognitive impairment in the elderly Giuseppe Verlato, M.D. Ph.D Department of Diagnostics and Public Health University of Verona Verona, Italy Mario Olivieri,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationHyperlipidemia in an Otherwise Healthy 80 Year-Old Patient. Theodore D Fraker, Jr, MD Professor of Medicine
Hyperlipidemia in an Otherwise Healthy Theodore D Fraker, Jr, MD Professor of Medicine Orlando, Florida October 7-9, 2011 80-Year-Old Patient Primary Prevention Issues in the Elderly: Coronary artery disease
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationHae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.
Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationSUPPLEMENTARY APPENDIX
Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 23 million people and more than 100,000 cases of dementia SUPPLEMENTARY APPENDIX Supplementary Methods Newcastle
More informationChapter 1. Introduction
The older people get, the bigger the chance of losing cognitive abilities and ultimately to develop dementia. Increasing age is the largest known risk factor of dementia, with a prevalence of 1% in people
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationEffects of whole grain intake on weight changes, diabetes, and cardiovascular Disease
Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease Simin Liu, MD, ScD Professor of Epidemiology and Medicine Director, Center for Global Cardiometabolic Health Brown
More informationPrevalence and Impact of Medical Comorbidity in Alzheimer s Disease
Journal of Gerontology: MEDICAL SCIENCES 2002, Vol. 57A, No. 3, M173 M177 Copyright 2002 by The Gerontological Society of America Prevalence and Impact of Medical Comorbidity in Alzheimer s Disease P.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationComparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes
Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes Joshua A Salomon, Anushka Patel, Bruce Neal, Paul Glasziou, Diederick E. Grobbee,
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationLongitudinal Trajectories of Cholesterol from Midlife through Late Life according to Apolipoprotein E Allele Status
Int. J. Environ. Res. Public Health 2014, 11, 10663-10693; doi:10.3390/ijerph111010663 OPEN ACCESS Article International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph
More information!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants
Aggregate Report Fasting Biometric Screening CLIENTXXXX May 2, 2014 21,000 participants Contact:404.636.9437~Website:www.atlantahealthsys.com RISK FACTOR QUESTIONNAIRE Participants Percent Do not exercise
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationSupplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationAnalyzing diastolic and systolic blood pressure individually or jointly?
Analyzing diastolic and systolic blood pressure individually or jointly? Chenglin Ye a, Gary Foster a, Lisa Dolovich b, Lehana Thabane a,c a. Department of Clinical Epidemiology and Biostatistics, McMaster
More informationEvaluation of Preventive Care Program for Cognitive Function Decline among Community-dwelling Frail Elderly People A Pilot Study
Journal of Japan Academy of Community Health Nursing Vol. 9, No. 2, pp. 87 92, 2007 Evaluation of Preventive Care Program for Cognitive Function Decline among Community-dwelling Frail Elderly People A
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationTitle. CitationAustralasian Journal on Ageing, 31(3): Issue Date Doc URL. Rights. Type. File Information
Title Randomised controlled pilot study in Japan comparing with a home visit with conversation alone Ukawa, Shigekazu; Yuasa, Motoyuki; Ikeno, Tamiko; Yo Author(s) Kishi, Reiko CitationAustralasian Journal
More informationStatins after 80 years old. Pros/Cons symposium. 13 th EUGMS Congress Nice Sept 2017
Statins after 80 years old Pros/Cons symposium 13 th EUGMS Congress Nice 20-22 Sept 2017 Athanasios Benetos Conflict of interest: None The Statinissean War Two fearless fighters Athanasios the Athenian
More informationMidlife vascular risk factors and Alzheimer s disease in later life: longitudinal, population based study
Midlife vascular risk factors and Alzheimer s disease in later life: longitudinal, population based study Miia Kivipelto, Eeva-Liisa Helkala, Mikko P Laakso, Tuomo Hänninen, Merja Hallikainen, Kari Alhainen,
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationLong-term follow-up studies suggest that elevated blood
Decline in Blood Pressure Over Time and Risk of Dementia A Longitudinal Study From the Kungsholmen Project Chengxuan Qiu, MD, PhD; Eva von Strauss, PhD; Bengt Winblad, MD, PhD; Laura Fratiglioni, MD, PhD
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationUse of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study Fn1 C. Cramer, PhD M.N. Haan, DrPH S. Galea, MD, DrPH K.M. Langa, MD, PhD J.D. Kalbfleisch, PhD Address
More informationCardiovascular Disease Risk Factors:
Cardiovascular Disease Risk Factors: Risk factors are traits or habits that increase a person's chances of having cardiovascular disease. Some risk factors can be changed. These risk factors are high blood
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationBaseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston
Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More information/ffl. Cohort Study of Vitamin C Intake and Cognitive Impairment
/ffl American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 1 Printed in U.S.A. A BRIEF ORIGINAL CONTRIBUTION
More informationAssociation of statin use with cognitive decline in elderly African Americans
Association of statin use with cognitive decline in elderly African Americans S.J. Szwast, MD H.C. Hendrie, MB, ChB, DSc K.A. Lane, MS S. Gao, PhD S.E. Taylor, MA F. Unverzagt, PhD J. Murrell, PhD M. Deeg,
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationNEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.
NEXT-Link DEMENTIA A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA NEXT-Link DEMENTIA is a network of Danish
More informationDECREASED SERUM LIPIDS IN PATIENTS WITH PROBABLE ALZHEIMER'S DISEASE
& DECREASED SERUM LIPIDS IN PATIENTS WITH PROBABLE ALZHEIMER'S DISEASE Orhan Lepara¹*, Amina Valjevac¹, Azra Alajbegović², Asija Zaćiragić¹, Emina Nakaš-Ićindić¹ ¹ Institute of Physiology and Biochemistry,
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationEpidemiologic Measure of Association
Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationEFFECT OF LYCOPENE IN TOMATO SOUP AND TOMATO JUICE ON THE LIPID PROFILE OF HYPERLIPIDEMIC SUBJECTS
EFFECT OF LYCOPENE IN TOMATO SOUP AND TOMATO JUICE ON THE LIPID PROFILE OF HYPERLIPIDEMIC SUBJECTS Nora Vigasini, Assistant Professor, Department of Home Science, Women s Christian College, Chennai, noravigas@gmail.com
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationEffectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
More informationChapter 4. Cognitive decline precedes late-life longitudinal changes in vascular risk factors
Cognitive decline precedes late-life longitudinal changes in vascular risk factors P. van Vliet, R.G.J. Westendorp, D. van Heemst, A.J.M. de Craen, A.M. Oleksik J Neurol Neurosurg Psychiatry 2010;81:1028-1032
More informationImproving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies
Improving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies Megan Willson, PharmD, BCPS; Catrina Schwartz, PharmD, BS; Jennifer Robinson, PharmD Spokane,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationThe leading cause of death in the United States is coronary
Overcoming Inertia: Improvement in Achieving Target Low-density Lipoprotein Cholesterol Kenneth C. Goldberg, MD; Stephanie D. Melnyk, PharmD; and David L. Simel, MD, MHS Objective: To improve lipid management
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationBlood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan.
Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan. Manabu Izumi, Kazuo Suzuki, Tetsuya Sakamoto and Masato Hayashi Jichi Medical University
More informationASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
More informationSecrets of delaying aging and living disease free Part 1
Secrets of delaying aging and living disease free Part 1 Roman Pawlak, Ph.D, RD www.drromanpawlak.com Aging results in profound changes that effect all systems, organs and tissues. Pawlak R. Forever young.
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationWhy would caregivers not want to treat their relative's Alzheimer's disease?
University of Pennsylvania ScholarlyCommons Neuroethics Publications Center for Neuroscience & Society 10-1-2003 Why would caregivers not want to treat their relative's Alzheimer's disease? Jason Karlawish
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Plasma Levels of -Amyloid (1-4), -Amyloid (1-42), and Total -Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins Kina Höglund, MSc;
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Cognitive impairment evaluated with Vascular Cognitive Impairment Harmonization Standards in a multicenter prospective stroke cohort in Korea Supplemental Methods Participants From
More informationHypertriglyceridemia and the Related Factors in Middle-aged Adults in Taiwan
1 Hypertriglyceridemia and the Related Factors in Middle-aged Adults in Taiwan Cheng-Chieh Lin, Tsai-Chung Li 2, Shih-Wei Lai, Kim-Choy Ng 1, Kuo-Che Wang, Chiu-Shong Liu Department of Community Medicine,
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationThe Impact of Smoking on Acute Ischemic Stroke
Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease
More informationObjective 4/22/2019. Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation.
Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Dereck Salisbury, PhD Assistant Professor, Clinical Exercise Physiologist Director: Laboratory
More informationInteraction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation
Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Dereck Salisbury, PhD Assistant Professor, Clinical Exercise Physiologist Director: Laboratory
More information